Skip to main navigation Skip to main content
  • KAPS
  • E-Submission

APS : Advances in Pediatric Surgery

OPEN ACCESS
ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS

Articles

The Korean Association of Pediatric Surgeons, Seoul, Korea.

Correspondence to Jung-Tak Oh. Department of Pediatric Surgery, Severance Children's Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea. jtoh@yuhs.ac
• Received: December 6, 2019   • Accepted: December 6, 2019

Copyright © 2019 Korean Association of Pediatric Surgeons

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 171 Views
  • 1 Download
  • 1 Crossref
next

Citations

Citations to this article as recorded by  Crossref logo
  • Analysis of Pediatric Surgery Using the National Healthcare Insurance Service Database in Korea: How Many Pediatric Surgeons Do We Need in Korea?
    Chaeyoun Oh, Sanghoon Lee, Hye Kyung Chang, Soo Min Ahn, Kyunghee Chae, Sujeong Kim, Sukil Kim, Jeong-Meen Seo
    Journal of Korean Medical Science.2021;[Epub]     CrossRef

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Sacrococcygeal Teratoma: A Survey by the Korean Association of Pediatric Surgeons in 2018
Adv Pediatr Surg. 2019;25(2):35-43.   Published online December 18, 2019
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:
Include:
Sacrococcygeal Teratoma: A Survey by the Korean Association of Pediatric Surgeons in 2018
Adv Pediatr Surg. 2019;25(2):35-43.   Published online December 18, 2019
Close

Figure

  • 0
  • 1
Sacrococcygeal Teratoma: A Survey by the Korean Association of Pediatric Surgeons in 2018
Image Image
Fig. 1 Hospital distribution of the patients with sacrococcygeal teratoma who underwent surgical treatment.
Fig. 2 Summary of treatments and prognoses. SCT, sacrococcygeal teratoma; F/U, follow-up.
Sacrococcygeal Teratoma: A Survey by the Korean Association of Pediatric Surgeons in 2018

The list of topics addressed at each annual meeting of the Korean Association of Pediatric Surgeons since 1991

Year and topic
1991 Current situation in Korean pediatric surgery 2005a) Necrotizing enterocolitis
1992 Inguinal hernia 2006a) Acute appendicitis
1993 Hirschsprung disease 2007 Prospect of pediatric surgery
1994 Anorectal malformation 2008 Inguinal hernia
1995a) Esophageal atresia and tracheoesophageal fistula 2009 Hirschsprung disease
1996a) Branchial anomalies 2010a) Intestinal atresia
1997a) Infantile hypertrophic pyloric stenosis 2011a) Biliary atresia
1998a) Intestinal atresia 2012 Statistics of pediatric surgery disease
1999a) Anorectal malformations 2013a) Minimally invasive surgery
2000a) Index cases in pediatric surgery 2014a) Newborns surgery with congenital anomalies
2001a) Biliary atresia 2015a) Neonate congenital Bochdalek hernia
2002a) Choledochal cyst 2016 Esophageal atresia with tracheoesophageal fistula
2003a) Congenital posterolateral diaphragmatic hernia 2017 Choledochal cyst
2004 Trend of pediatric surgery disease 2018a) Sacrococcygeal teratoma

a)These studies were published in Advances in Pediatric Surgery.

Patient demographics

Characteristic Value
Sex (M:F) 1:2.71 (51:138)
Gestational age (wk, n=176) 37.9±2.8
Birth weight (kg, n=179) 3.18±0.52 (0.97–4.71)
Mode of delivery
Normal spontaneous vaginal delivery 76 (40.2)
C-section 100 (52.9)
Unknown 23
Accompanied malformation 29/189a) (15.3)
Cardiovascular 8
Gastrointestinal 5
Genitourinary 4
Musculoskeletal 4
Chromosomal 2
Other 6
Currarino syndrome 15
Age at time of surgery
<29 day 137
29 day–2 mo 6
2–3 mo 7
3–12 mo 12
>12 mo 27

Values are presented as mean±standard deviation or number (%).

a)Including multiple selection.

Preoperative evaluation and treatment

Characteristic Total Neonate Old-age
Clinical presentationa) (n=182) (n=132) (n=26)
Abdominal pain/distension 13 (7.1) 5 (3.8) 2 (7.7)
Mass 145 (79.7) 120 (90.9) 11 (42.3)
Constipation 10 (5.5) 0 5 (19.2)
No symptoms 9 (4.9) 7 (5.3) 1 (3.8)
Other 14 (7.7) 1 (0.8) 9 (34.6)
Prenatal diagnosis in neonatea) 113/135 (85.6)
Prenatal US 113
Prenatal MRI 3 (2.2)
In-utero procedure 11/135 (8.1)
RFA 8
Aspiration 2
Cystic-amniotic shunt 1
Diagnostic work-up after deliverya) (n=182) (n=132) (n=26)
US 105 (57.7) 83 (62.9) 10 (38.5)
CT 16 (8.8) 9 (6.8) 5 (19.2)
MRI 159 (87.4) 112 (84.8) 24 (92.3)
Preoperative biopsy 4 (2.2) 0 4 (15.4)
Other 3 (1.6) 2 (1.5) 1 (3.8)
Pre-op AFP (ng/mL) (n=138) (n=111) (n=14)
Mean±SD 87,658±77,076 20,287±42,396
Median (range) 64,745 (0.8–600,000) 2.1 (0.8–150,730)
Preoperative treatment (n=189) (n=137) (n=27)
Preoperative chemotherapy 6 6
Preoperative embolization 1 1
Preoperative chemotherapy and ASCTb) 1 1
Preoperative complications (n=189) (n=137) (n=27)
Yes 30 (15.9) 26 (19.0) 1 (3.7)
No 159 (84.1) 111 (81.0) 26 (96.3)

Values are presented as number (%).

US, ultrasound; MRI, magnetic resonance imaging; RFA, radiofrequency ablation; CT, computed tomography; AFP, α-fetoprotein; SD, standard deviation; ASCT, autologous stem cell transplantation.

a)Including multiple selection; b)Autologous stem cell transplantation.

Operative treatment

Characteristic Total (n=189) Neonate (n=137) Old-age (n=27)
Age at time of surgery (day)
Mean 305.9±957.1 6.9±9.2 1,985.3±1,784.9
Median 6 (0–7,217) 4 (0–63) 1,426 (397–7,217)
No. of operations
1 145 (76.7) 106 (77.4) 21 (77.8)
2 37 (19.6) 27 (19.7) 3 (11.1)
3 6 (3.2) 4 (2.9) 2 (7.4)
5 1 (0.5) 0 1 (3.7)
Body weight at time of surgery (kg)
Mean±SD 6.2±8.8 3.1±0.6 22.0±15.9
Median (range) 3 (2–69) 3 (2–5) 16 (8–69)
Operation time
Mean±SD 148.0±89.6 150.3±82.8 155.7±129.4
Median (range) 125 (20–590) 132 (20–410) 110 (34–590)
Mode of surgery
Perineal approach 177 (93.7) 131 (95.6) 23 (85.2)
Perineal+laparotomy/laparoscopic 9 5 2
Others 3 1 2
Results of operation
Complete excision 159 (84.1) 116 (84.7) 23 (85.2)
Complete excision with spillage 12 (6.3) 6 (4.4) 2 (7.4)
Incomplete excision 18 (9.5) 15 (10.9) 2 (7.4)
Intraoperative complications 21/189 (11.1) 15/137 (10.9) 3/27 (11.1)
Bleeding 8 (38.1) 6 (40.0) 2 (66.7)
CSF leakage 4 (19.0) 1 (6.7) 1 (33.3)
CPCR 4 (19.0) 4 (26.7) 0
Other complications 6 (28.6) 5 (33.3) 0
Postoperative complicationsa) 30/189 24/137 3/27
Bleeding 3 (10.0) 3 (12.5) 0 (0)
Wound problem 17 (56.7) 14 (58.3) 1 (33.3)
Intestinal obstruction 1 (3.3) 1 (4.2) 0 (0)
DIC 5 (16.7) 5 (20.8) 0 (0)
Other 7 (23.3) 4 (16.7) 2 (66.7)
Reoperation during hospitalization 9/189 (4.8) 7/137 (5.1) 1/27 (3.7)
Postoperative chemotherapy 11 (5.8) 5 (3.6) 4 (14.8)

Values are presented as number (%).

SD, standard deviation; CSF, cerebrospinal fluid; CPCR, cerebral resuscitation; DIC, disseminated intravascular coagulation.

a)Including multiple selection.

Tumor characteristics

Characteristic Total (n=189) Neonate (n=137) Old-age (n=27)
Pathology of tumor
Mature teratoma 138 (73.0) 103 (75.2) 16 (59.3)
Immature teratoma 33 (17.5) 30 (21.9) 2 (7.4)
Grade 1 4 (13.8) 4 (14.8) 0 (0)
Grade 2 10 (34.5) 8 (29.6) 1 (100)
Grade 3 15 (51.7) 15 (55.6) 0 (0)
Grade unknown 4 (13.8) 3 1
Mixed 4 (2.1) 2 (1.5) 0
Malignant (yolk sac) 2 (1.1) 1 (0.7) 1 (3.7)
Othera) 12 (6.3) 1 (0.7) 8 (29.6)
Largest tumor length (cm) 6.8±4.8 7.9±5.1 4.2±4.8
Type of tumor component
Cystic type 63 (34.1) 43 (31.6) 9 (37.5)
Predominantly cystic mixed type 61 (33.0) 48 (35.3) 6 (25.0)
Predominantly solid mixed type 32 (17.3) 29 (21.3) 1 (4.2)
Solid type 29 (15.7) 16 (11.8) 8 (33.3)
Unknown 4 1 2
Altman classification
I 68 (36.0) 53 (38.7) 8 (29.6)
II 51 (27.0) 47 (34.3) 2 (7.4)
III 25 (13.2) 21 (15.3) 1 (3.7)
IV 45 (23.8) 16 (11.7) 16 (59.3)

Values are presented as number (%) or mean±standard deviation.

a)Epidermal cyst (2), lipoma (2), lipoblastoma (2), duplication cyst (1), solitary fibrous tumor (1), infantile fibrosarcoma (1), lipomyelomeningocele (1), lymphangioma (1), epithelioid hemangioendothelioma (1).

Postoperative treatment and follow-up

Characteristic Total (n=189) Neonate (n=137) Old-age (n=27)
Postoperative follow-up (mo)
Age at last follow-up 47.9±38.9 (median 41, range 0–243)
Postoperative follow-up 37.9±27.6 (median 34, range 0–112)
Follow-up methoda)
US 89 (47.1) 66 (48.2) 13 (48.1)
CT 23 (12.2) 17 (12.4) 4 (14.8)
MRI 98 (51.9) 77 (56.2) 10 (37.3)
PET 5 (2.6) 3 (2.2) 2 (7.4)
Other 4 (2.1) 3 (2.2) 0 (0)
Follow-up interval (mo)
1–3 25
4–6 30
7–12 37
>12 14
Tumor recurrence 39 (20.6) 28 5
Detection of tumor recurrence
Physical examination 1 (2.6) 1 (3.6) 0 (0)
Elevated tumor marker 3 (7.7) 3 (10.7) 0 (0)
MRI 27 (69.2) 20 (71.4) 5 (100)
U/S 7 (17.9) 4 (14.3) 0 (0)
Other 1 (2.6) 0 (0) 0 (0)
Treatment of tumor recurrence
Excision 21 (53.8) 14 (50.0) 3 (60.0)
Excision+CTx 12 (30.8) 9 (32.1) 1 (20.0)
CTx only 2 (5.1) 1 (3.6) 1 (20.0)
Observation 2 (5.1) 2 (7.1) 0 (0)
Other 2 (5.1) 2 (7.1) 0 (0)
Long-term functional complicationsa) 44
Constipation 21
Soiling 14
Urinary incontinence 7
Lower extremity weakness 5
Other 7

Values are presented as mean±standard deviation or number (%).

US, ultrasound; CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography; CTx, chemotherapy.

a)Including multiple selection.

Recurrent tumor pathology

Characteristic Total (n=33) Neonate (n=23) Old-age (n=4)
Mature 19 (57.6) 15 (78.9) 1 (25.0)
Original pathology Mature (10), immature (8), mixed (1)
Immature 2 (6.1) 2 (8.7) 0 (0)
Original pathology Mature (1), immature (1)
Malignant (yolk sac) 6 (18.2) 3 (13.0) 1 (25.0)
Original pathology Mature (3), immature (1), yolk sac (2)
Mixed 1 (3.0) 1 (4.3) 0 (0)
Original pathology Mature (1)
Othera) 5 (15.2) 2 (8.7) 2 (50.0)
Original pathology Mature (3), immature (1), epithelioid hemangioendothelioma (1)

a)Epithelioid hemangioendothelioma (1), inflamed granulation tissue (1), lipomeningomyelocele (1), lipoma (1), no evidence of residual teratoma but r/o recurred tumor on follow-up magnetic resonance imaging (1).

Questionnaire for sacrococcygeal teratoma

Questionnaire No.
1. Which of the following tests are the most important for the preoperative diagnosis of sacrococcygeal teratoma (excluding physical findings and multiple selections available)?
① AFP 12
② US 4
③ CT 6
④ MRI 16
⑤ Biopsy 0
2. Have you needed to do a coccyx resection for patients with sacrococcygeal teratoma? please describe the method and extent of resection.
① No resection 0
② Resection 22
Method: electrical cautery and en bloc resection
3. Who do patients follow-up with after surgery?
① Pediatric surgeon 14
② Pediatrician 4
③ Other—both pediatric surgeons and pediatricians (especially in cases of immature or malignant pathologies) 4
4. What tests are performed after surgery? (Multiple options are possible.)
① AFP 21
② US 11
③ CT 4
④ MRI 12
⑤ Other—rectal exam 1
5. What is the timing (interval) of the postoperative follow-up?
① Every 6 months after surgery 9
② Every year after surgery 7
③ Every 2 years after surgery 0
④ Less than every 6 months after surgery 4
6. How long after surgery do you follow-up? (n=20)
① Until 1 year after surgery 0
② Until 2 years after surgery 1
③ Until 3 years after surgery 3
④ Until 4 years after surgery 0
⑤ Until 5 years after surgery 13
⑥ Mature-3 years, immature-5 years 3
7. Do you have any experience with minimally invasive surgery for sacrococcygeal teratoma?
① Yes 5
② No 17

AFP, α-fetoprotein; US, ultrasound; CT, computed tomography; MRI, magnetic resonance imaging.

Table 1 The list of topics addressed at each annual meeting of the Korean Association of Pediatric Surgeons since 1991

a)These studies were published in Advances in Pediatric Surgery.

Table 2 Patient demographics

Values are presented as mean±standard deviation or number (%).

a)Including multiple selection.

Table 3 Preoperative evaluation and treatment

Values are presented as number (%).

US, ultrasound; MRI, magnetic resonance imaging; RFA, radiofrequency ablation; CT, computed tomography; AFP, α-fetoprotein; SD, standard deviation; ASCT, autologous stem cell transplantation.

a)Including multiple selection; b)Autologous stem cell transplantation.

Table 4 Operative treatment

Values are presented as number (%).

SD, standard deviation; CSF, cerebrospinal fluid; CPCR, cerebral resuscitation; DIC, disseminated intravascular coagulation.

a)Including multiple selection.

Table 5 Tumor characteristics

Values are presented as number (%) or mean±standard deviation.

a)Epidermal cyst (2), lipoma (2), lipoblastoma (2), duplication cyst (1), solitary fibrous tumor (1), infantile fibrosarcoma (1), lipomyelomeningocele (1), lymphangioma (1), epithelioid hemangioendothelioma (1).

Table 6 Postoperative treatment and follow-up

Values are presented as mean±standard deviation or number (%).

US, ultrasound; CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography; CTx, chemotherapy.

a)Including multiple selection.

Table 7 Recurrent tumor pathology

a)Epithelioid hemangioendothelioma (1), inflamed granulation tissue (1), lipomeningomyelocele (1), lipoma (1), no evidence of residual teratoma but r/o recurred tumor on follow-up magnetic resonance imaging (1).

Table 8 Questionnaire for sacrococcygeal teratoma

AFP, α-fetoprotein; US, ultrasound; CT, computed tomography; MRI, magnetic resonance imaging.